Sonexa Raises $30M Series A to Fund its Alzheimer's Trials

Morrison, Trista
February 2008
BioWorld Today;2/1/2008, Vol. 19 Issue 22, p1
The article reports on the success of start-up Sonexa Therapeutics Inc. to raise $30 million in a Series A financing to in-license and fund clinical trials with a new small molecule for Alzheimer's disease. The Series A financing was led by Domain Associates LLC, Scale Venture Partners and Alta Partners.


Related Articles

  • aTyr Pharma Raises $23M Series C for New Biologics. Morrison, Trista // BioWorld Today;10/26/2010, Vol. 21 Issue 207, p3 

    The article reports on the Series C financing round of aTyr Pharma Inc. which raised 23 million U.S. dollars. Investors were interested in the company because of its research on physiocrines, a new type of endogenous proteins which has a role in extracellular signaling. Investors that...

  • Investors Open Wallets For Altair Therapeutics. Chambers, Heather // San Diego Business Journal;11/16/2009, Vol. 30 Issue 46, p6 

    The article reports on 17 million dollars in Round A financing secured by San Diego-based Altair Therapeutics in California. Altair stated that it will use the funding to finalize midstage trials for its lead drug candidate in treating asthma and runny nose. It cites that Domain Associates LLC...

  • Esperion Spins Out of Pfizer, Brings in $22.8M in Series A. Turner, Tiffany // BioWorld Today;5/2/2008, Vol. 19 Issue 86, p1 

    The article reports that the disinvestment of Esperion Therapeutics Inc. by Pfizer Inc. resulted in a $22.8 million Series A financing round in May 2008. The deal was co-led by Aisling Capital, Alta Partners and Domain Associates. Reportedly, Pfizer was responsible in helping Esperion develop...

  • Syndax Secures a Sweet $26.6M Series B. Powers, Marie // BioWorld Today;8/28/2013, Vol. 24 Issue 165, p1 

    The article reports on the 26.6 million dollars raised by clinical-stage pharmaceutical firm Syndax Pharmaceuticals Inc. via a Series B financing deal in August 2013. Domain Associates was one of the investors involved in the deal. According to Syndax Chief Executive Officer (CEO) Arlene M....

  • AML Remissions Set Up Celator for $20M Series D. Shaffer, Catherine // BioWorld Today;9/2/2010, Vol. 21 Issue 170, p1 

    The article reports that 20 million U.S. dollars have been raised by Celator Pharmaceuticals Inc. in its Series D financing. Proceeds will be used by the company to finance clinical trials for its lead compound CPX-351, a combination of cytarabine and daunorubicin. Investors in the financing...

  • Taligen Gets $65M Series B for Complement Programs. Morrison, Trista // BioWorld Today;2/4/2008, Vol. 19 Issue 23, p1 

    The article reports that pharmaceutical firm Taligen has raised $65 million in Series B financing. The company will use the fund to complete its preclinical work and move into clinical trials with its drugs intended to fight diseases associated with complement proteins. The investment will come...

  • Atyr Raises $49M in Venture Round for Rare Disease Drugs. Boggs, Jennifer // BioWorld Today;7/29/2013, Vol. 24 Issue 143, p1 

    The article reports on the oversubscribed 49 million dollars Series D venture round announced by privately held Atyr Pharma Inc. in July 2013 to support work on its rare disease drugs pipeline. According to Atyr chief executive officer (CEO) John Mendle, existing investors such as Alta Partners...

  • Financings Roundup.  // BioWorld Today;8/11/2009, Vol. 20 Issue 153, p5 

    The article reports on the venture capital fund obtained by Princeton, New Jersey-based Domain Associates LLC. The 500 million U.S. dollar fund is devoted exclusively to the life sciences industry. According to Domain, it would continue to focus on early stage companies in the drug and device...

  • Pfizer jettisons Esperion. Shaffer, Catherine // Nature Biotechnology;Jul2008, Vol. 26 Issue 7, p724 

    This article describes a decision by Pfizer pharmaceutical company to spin off Esperion Therapeutics Inc. Esperion was purchased by Pfizer Inc. in March, 2004, but since the acquisition that company has not moved forward in the development of pharmaceuticals. The history of Esperion...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics